An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985.

  title={An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985.},
  author={Alfred P. Hallstrom and Leonard A. Cobb and B. H. Yu and W. Douglas Weaver and Carol Fahrenbruch},
  journal={The American journal of cardiology},
  volume={68 10},
Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.
Antiarrhythmic Impact of Anti-Ischemic, Anti-Failure and Other Cardiovascular Strategies
A shift in focus from agents that suppress ventricular arrhythmias to agents that alter or limit the arrhythmic milieu in some ways parallels the evolution of the management of congestive heart failure.
The Role of EP-Guided Therapy in Ventricular Arrhythmias: Beta-Blockers, Sotalol, and ICD's
The ongoing BEST Trial will give further responses about the interaction between EP study and metoprolol effect compared to ICD in patients post myocardial infarction also focusing on tolerability and compliance of the beta-blocking therapy in patients with low ejection fraction.
An Overview of Secondary Prevention Implantable Cardioverter-Defibrillator Trials: AVID, CIDS and CASH
Patients with previous sustained ventricular tachyarrhythmias only account for < 1% of patients who die suddenly, and the benefits of β-blockers are supported by their known effects in prolonging survival in high-risk patients post-myocardial infarction or with congestive heart failure (CHF).


Antiarrhythmic Drug Therapy in Survivors of Prehospital Cardiac Arrest: Comparison of Effects on Chronic Ventricular Arrhythmias Recurrent Cardiac Arrest
We studied the long-term effects of membrane-active antiarrhythmic agents on chronic ventricular arrhythmias in patients who have survived prehospital cardiac arrest. Among 16 patients treated with a
Effect of antiarrhythmic drugs on mortality after myocardial infarction.
  • C. Furberg
  • Medicine, Biology
    The American journal of cardiology
  • 1983
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
It is concluded that neither encainide nor flecainide should be used in the treatment of patients with asymptomatic or minimally symptomatic ventricular arrhythmia after myocardial infarction, even though these drugs may be effective initially in suppressing ventricular arrhythmia.
Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction.
The risk of sudden death is relatively greater for those patients who have had a myocardial infarction than for those who have not, and the presence of premature ventricular contractions after MI has been shown to be a risk.
Considerations in the Long‐Term Management of Survivors of Cardiac Arrest a
Clearly, efforts to lessen the mortality of patients who have been resuscitated from out-of-hospital cardiac arrest are important, not only for the particular patients themselves, but also in an effort to develop rational, prophylactic interventions for the large numbers of patients with coronary heart disease who are at risk for the development of sudden cardiac death.
Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest.
The largest single cause of death in the United States is sudden cardiac death, and the number of sudden deaths is higher in women than in the general population.
Antiarrhythmic therapy: quinidine gluconate vs procainamide.
2. Charlier R, Delaunois G, Bauthier J: Incidence de l'amiodarone et de quelques beta-bloquants sur la contractilite du ventricule gauche chez le chien.
Prehospital Ventricular Defibrillation
The vast majority of deaths occurring seconds to minutes after the onset of acute symptoms result from ventricular fibrillation, and this type of death is known as a sudden death.